SAN DIEGO, Dec. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced that its Phase 3 KINECT ®-DCP study evaluating the efficacy, safety, and tolerability of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results